Articles

Lilly CEO: Drugmakers getting bum rap

Eli Lilly and Co. CEO John Lechleiter told Wall Street analysts recently that, while there have been “individual huge drug price increases,” the overall cost of drugs is rising very slowly and remains a small part of overall U.S. health care spending.

Read More

Lilly expands R&D outside Indy—again

State and city leaders spend millions each year to entice companies to move here and add jobs here. But for the second time in three months, Eli Lilly and Co. has shown that the biggest attraction to a company is talented workers.

Read More

Lilly faces moment of truth this week

The Indianapolis-based drugmaker on Wednesday will release new data from patients taking its Alzheimer’s drug that could show whether the drug has slowed the progression of their disease. That will show investors whether the 45 percent rise in Lilly’s stock price over the past year is justified.

Read More

Indiana’s medical research ‘trade deficit’

Indiana's life sciences companies are spending four times more on medical research than the state's hospitals, doctors and univerities are receiving from such companies for research projects. That means Indiana is missing out on more than $80 million a year.

Read More

Killing obesity without coercion

Top-down culture change only works in North Korea, says the head of a group of local CEOs that is working broadly and subtly, not tyrannically, to improve Indy’s culture of eating and exercising.

Read More

Lechleiter: It’s morning at Eli Lilly

Lilly CEO John Lechleiter kicked off the company’s quarterly conference call with investors and analysts by declaring an end to the “unprecedented challenge” that Lilly lived through the past four years.

Read More